drugset / Trial / NCT05082909

Addition of Probenecid to Penicillin-V Therapy

NCT05082909

Phase 1/2 Completed 21 enrolled Imperial College London
RandomizedCrossoverOpen-labelTreatment

Summary

This study aims to build on previous work characterising the PK of penicillin-V to explore the potential impact of probenecid on PK-PD target attainment. Achievement of the aims of this study would provide data to support the design of experimental studies exploring the clinical impact of probenecid on treatment outcomes and also provide a rationale for exploration of probenecid's effects on a larger number of beta-lactam antibiotics. Hypothesis: Addition of probenecid to oral phenoxymethylpenicillin (penicillin-V) has a clinically relevant effect on pharmacokinetic-pharmacodynamic (PK-PD) target attainment.

Timeline

Start
2021-12-21
Primary completion
2022-07-07
Completion
2022-07-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Probenecid Small molecule 500 mg Oral